Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency.

Frigstad SO, Haaber A, Bajor A, Fallingborg J, Hammarlund P, Bonderup OK, Blom H, Rannem T, Hellström PM.

Gastroenterol Res Pract. 2017;2017:4585164. doi: 10.1155/2017/4585164. Epub 2017 Oct 22.

2.

Effects of conventional and a novel colonic-release bile acid sequestrant, A3384, on fibroblast growth factor 19 and bile acid metabolism in healthy volunteers and patients with bile acid diarrhoea.

Appleby RN, Bajor A, Gillberg PG, Graffner H, Simrén M, Ung KA, Walters J.

United European Gastroenterol J. 2017 Apr;5(3):380-388. doi: 10.1177/2050640616662432. Epub 2016 Jul 26.

3.

[Retinal Vein Occlusion - Which Treatment When?]

Bajor A, Pielen A, Danzmann L.

Klin Monbl Augenheilkd. 2017 Oct;234(10):1259-1265. doi: 10.1055/s-0042-123834. Epub 2017 Apr 4. German.

PMID:
28376554
4.

Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients.

Angelison L, Almer S, Eriksson A, Karling P, Fagerberg U, Halfvarson J, Thörn M, Björk J, Hindorf U, Löfberg R, Bajor A, Hjortswang H, Hammarlund P, Grip O, Torp J, Marsal J, Hertervig E; Swedish Organization for the Study of Inflammatory Bowel diseases (SOIBD).

Aliment Pharmacol Ther. 2017 Feb;45(4):519-532. doi: 10.1111/apt.13893. Epub 2016 Dec 27.

5.

Immobilization and detection of platelet-derived extracellular vesicles on functionalized silicon substrate: cytometric and spectrometric approach.

Gajos K, Kamińska A, Awsiuk K, Bajor A, Gruszczyński K, Pawlak A, Żądło A, Kowalik A, Budkowski A, Stępień E.

Anal Bioanal Chem. 2017 Feb;409(4):1109-1119. doi: 10.1007/s00216-016-0036-5. Epub 2016 Nov 7.

6.

Fecal incontinence in irritable bowel syndrome: Prevalence and associated factors in Swedish and American patients.

Simrén M, Palsson OS, Heymen S, Bajor A, Törnblom H, Whitehead WE.

Neurogastroenterol Motil. 2017 Feb;29(2). doi: 10.1111/nmo.12919. Epub 2016 Aug 31.

7.

Listeria monocytogenes endophthalmitis - case report and review of risk factors and treatment outcomes.

Bajor A, Luhr A, Brockmann D, Suerbaum S, Framme C, Sedlacek L.

BMC Infect Dis. 2016 Jul 16;16:332. doi: 10.1186/s12879-016-1680-2. Review.

8.

Peripheral retinal non-perfusion and treatment response in branch retinal vein occlusion.

Abri Aghdam K, Reznicek L, Soltan Sanjari M, Framme C, Bajor A, Klingenstein A, Kernt M, Seidensticker F.

Int J Ophthalmol. 2016 Jun 18;9(6):858-62. doi: 10.18240/ijo.2016.06.12. eCollection 2016.

9.

[Orbital complication of acute sinusitis : Orbital cellulitis in a 10-year-old child].

Bajor A, Lang CP, Bültmann E, Framme C, Hufendiek K.

Ophthalmologe. 2017 Apr;114(4):365-369. doi: 10.1007/s00347-016-0296-7. German.

PMID:
27314239
10.

Review article: bile acid diarrhoea - pathogenesis, diagnosis and management.

Mottacki N, Simrén M, Bajor A.

Aliment Pharmacol Ther. 2016 Apr;43(8):884-898. doi: 10.1111/apt.13570. Epub 2016 Feb 24. Review.

11.

Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition.

Magnusson MK, Strid H, Sapnara M, Lasson A, Bajor A, Ung KA, Öhman L.

J Crohns Colitis. 2016 Aug;10(8):943-52. doi: 10.1093/ecco-jcc/jjw051. Epub 2016 Feb 19.

PMID:
26896085
12.

[Quantum of luck with a self-induced penetrating orbital injury].

Bajor A, Calvelli K, Janke E, Bialon P, Lang J, Bültmann E, Brunotte I, Framme C.

Ophthalmologe. 2016 Sep;113(9):772-4. doi: 10.1007/s00347-015-0211-7. German.

PMID:
26792786
13.

Are the definitions for chronic diarrhoea adequate? Evaluation of two different definitions in patients with chronic diarrhoea.

Stotzer PO, Abrahamsson H, Bajor A, Kilander A, Sadik R, Sjövall H, Simrén M.

United European Gastroenterol J. 2015 Aug;3(4):381-6. doi: 10.1177/2050640615580219.

14.

miR-145 Is a Promising Therapeutic Target to Prevent Cornea Scarring.

Ratuszny D, Gras C, Bajor A, Börger AK, Pielen A, Börgel M, Framme C, Blasczyk R, Figueiredo C.

Hum Gene Ther. 2015 Oct;26(10):698-707. doi: 10.1089/hum.2014.151. Epub 2015 Sep 16.

PMID:
26165705
15.

Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy.

Dahlén R, Magnusson MK, Bajor A, Lasson A, Ung KA, Strid H, Öhman L.

Scand J Gastroenterol. 2015;50(9):1118-26. doi: 10.3109/00365521.2015.1031167. Epub 2015 Apr 16.

PMID:
25877762
16.

Cultured blood T-cell responses predict anti-TNF therapy response in patients with ulcerative colitis.

Magnusson MK, Strid H, Isaksson S, Bajor A, Lasson A, Ung KA, Öhman L.

Aliment Pharmacol Ther. 2015 Jun;41(11):1149-61. doi: 10.1111/apt.13192. Epub 2015 Apr 8.

17.

Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C.

Magnusson MK, Strid H, Isaksson S, Bajor A, Lasson A, Ung KA, Öhman L.

J Crohns Colitis. 2015 Jan;9(1):56-65. doi: 10.1093/ecco-jcc/jju008. Epub 2014 Nov 26.

PMID:
25518051
18.

Authors' response: bile acids are important in the pathophysiology of IBS.

Bajor A, Törnblom H, Rudling M, Ung KA, Simrén M.

Gut. 2015 May;64(5):851-2. doi: 10.1136/gutjnl-2014-308037. Epub 2014 Jul 23. No abstract available.

PMID:
25056657
19.

CD25 and TNF receptor II reflect early primary response to infliximab therapy in patients with ulcerative colitis.

Magnusson MK, Dahlén R, Strid H, Isaksson S, Simrén M, Lasson A, Bajor A, Ung KA, Ohman L.

United European Gastroenterol J. 2013 Dec;1(6):467-76. doi: 10.1177/2050640613502962.

20.

Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS.

Bajor A, Törnblom H, Rudling M, Ung KA, Simrén M.

Gut. 2015 Jan;64(1):84-92. doi: 10.1136/gutjnl-2013-305965. Epub 2014 Apr 12.

PMID:
24727487
21.

Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life.

Befrits R, Wikman O, Blomquist L, Hjortswang H, Hammarlund P, Bajor A, Klintman D, Blom H.

Scand J Gastroenterol. 2013 Sep;48(9):1027-32. doi: 10.3109/00365521.2013.819442. Epub 2013 Jul 29.

PMID:
23889159
22.

Modulatory role of calreticulin as chaperokine for dendritic cell-based immunotherapy.

Bajor A, Tischer S, Figueiredo C, Wittmann M, Immenschuh S, Blasczyk R, Eiz-Vesper B.

Clin Exp Immunol. 2011 Aug;165(2):220-34. doi: 10.1111/j.1365-2249.2011.04423.x. Epub 2011 Jun 3.

23.

Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study.

Simrén M, Bajor A, Gillberg PG, Rudling M, Abrahamsson H.

Aliment Pharmacol Ther. 2011 Jul;34(1):41-50. doi: 10.1111/j.1365-2036.2011.04675.x. Epub 2011 May 5.

24.

Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain.

Krarup AL, Ny L, Astrand M, Bajor A, Hvid-Jensen F, Hansen MB, Simrén M, Funch-Jensen P, Drewes AM.

Aliment Pharmacol Ther. 2011 May;33(10):1113-22. doi: 10.1111/j.1365-2036.2011.04629.x. Epub 2011 Mar 16.

25.

Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial.

Johannesson E, Simrén M, Strid H, Bajor A, Sadik R.

Am J Gastroenterol. 2011 May;106(5):915-22. doi: 10.1038/ajg.2010.480. Epub 2011 Jan 4.

PMID:
21206488
26.

Bile acids: short and long term effects in the intestine.

Bajor A, Gillberg PG, Abrahamsson H.

Scand J Gastroenterol. 2010 Jun;45(6):645-64. doi: 10.3109/00365521003702734. Review.

PMID:
20334475
27.

Biliary sphincterotomy does not relate to diarrhoea or major changes in bile acid synthesis or plasma lipids.

Ung KA, Mottacki N, Rudling M, Bajor A.

Scand J Gastroenterol. 2009;44(9):1132-8.

PMID:
19811340
28.

Indirect evidence for increased mechanosensitivity of jejunal secretomotor neurones in patients with idiopathic bile acid malabsorption.

Bajor A, Ung KA, Ohman L, Simren M, Thomas EA, Bornstein JC, Sjövall H.

Acta Physiol (Oxf). 2009 Oct;197(2):129-37. doi: 10.1111/j.1748-1716.2009.01993.x. Epub 2009 Apr 27.

PMID:
19432585
29.

The bile acid turnover rate assessed with the (75)SeHCAT test is stable in chronic diarrhoea but slightly decreased in healthy subjects after a long period of time.

Bajor A, Kilander A, Sjövall H, Rudling M, Ung KA.

Dig Dis Sci. 2008 Nov;53(11):2935-40. doi: 10.1007/s10620-008-0256-4. Epub 2008 Apr 25.

PMID:
18437571
30.

Budesonide treatment is associated with increased bile acid absorption in collagenous colitis.

Bajor A, Kilander A, Gälman C, Rudling M, Ung KA.

Aliment Pharmacol Ther. 2006 Dec;24(11-12):1643-9. Epub 2006 Nov 10.

31.

Normal or increased bile acid uptake in isolated mucosa from patients with bile acid malabsorption.

Bajor A, Kilander A, Fae A, Gälman C, Jonsson O, Ohman L, Rudling M, Sjövall H, Stotzer PO, Ung KA.

Eur J Gastroenterol Hepatol. 2006 Apr;18(4):397-403. Erratum in: Eur J Gastroenterol Hepatol. 2007 Feb;19(2):185.

PMID:
16538111
32.

Overuse of acid suppressive therapy in hospitalised patients with pulmonary diseases.

Niklasson A, Bajor A, Bergendal L, Simrén M, Strid H, Björnsson E.

Respir Med. 2003 Oct;97(10):1143-50.

33.

[Bajor's test; a piece of log pierced by a safety pin].

BAJOR A.

Psyche Rev Int Sci Homme Psychanal. 1952 Nov;7(73):761. Undetermined Language. No abstract available.

PMID:
13027484

Supplemental Content

Support Center